What common feature is shared between the coverage of lymphoma and multiple myeloma?

Restaging is a common feature shared between the coverage of lymphoma and multiple myeloma. Restaging involves evaluating the disease status after treatment to determine the effectiveness of the therapy and to assess whether the disease has progressed or responded positively.

In both lymphoma and multiple myeloma, restaging is a crucial step in patient management. For lymphoma, restaging often includes imaging studies like PET scans to evaluate the presence of any residual disease or new lesions after treatment. Similarly, for multiple myeloma, restaging usually involves not only imaging to visualize bone lesions but also laboratory tests to monitor changes in disease markers such as serum protein levels and other relevant blood tests.

Maintaining a focus on restaging aligns with the overall treatment goals in both conditions, ensuring that clinicians can make informed decisions about ongoing therapy and patient prognosis.